Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma

NCT04522323 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT04522323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04522323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Combination With Axitinib in Subjects With Advanced Renal Cell Carcinoma
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 5, 2020
Completion date
September 26, 2025
Enrollment
67 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma